Loading...
•
Mar 31, 2025
NeoGenomics Q1 2025 Earnings Report
Estimated Revenue:$173M
+10.2% YoY
Estimated EPS:-$0.00985
+23.5% YoY
Key Takeaways
NeoGenomics reported a solid start to 2025, with consolidated revenue increasing 8% year-over-year to $168 million, driven by higher volume. The net loss decreased by 4% to $26 million, and adjusted EBITDA significantly increased by 102% to $7 million, indicating improved operational efficiency.
Consolidated revenue for Q1 2025 increased by 8% to $168 million compared to Q1 2024.
Net loss for the quarter decreased by 4% to $26 million.
Adjusted EBITDA saw a significant increase of 102%, reaching $7 million.
Average revenue per clinical test increased by 3% to $459, driven by higher value tests and strategic reimbursement initiatives.
Forward Guidance
The company revised its full-year 2025 guidance to reflect the acquisition of Pathline, LLC, increasing the revenue range.
Positive Outlook
- Full-year 2025 consolidated revenue guidance increased to a range of $747 million to $759 million.
- The acquisition of Pathline, LLC is expected to contribute $12 million to $14 million in revenue in 2025.
- Full-year 2025 Adjusted EBITDA guidance remains strong, ranging from $55 million to $58 million.
- Management expects to accelerate growth through portfolio expansion and upcoming product launches.
- Focus on customer experience and leveraging the sales force are expected to support future growth.
Challenges Ahead
- Full-year 2025 GAAP net loss guidance remains negative, ranging from $85 million to $77 million.
- Guidance is subject to adjustment and investors are cautioned against undue reliance on forward-looking statements.
- The business is subject to substantial risks and uncertainties.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...